© Cleveland Clinic 2019
For more data like this, visit clevelandclinic.org/hvioutcomes
HEART & VASCULAR
Volumes and outcomes from a sampling of centers in Cleveland Clinic’s Miller Family Heart & Vascular Institute
Heart Failure
Vitals
13,857
Outpatient heart failure visits
(2018 data unless otherwise noted)
289
Referrals for heart transplant or LVAD placement
102
Listings for heart transplant — up 32% from prior year
52
Heart transplants
91.5%
1-year heart transplant patient survival, vs. 91.5% U.S. rate
90.4%
3-year heart transplant patient survival, vs. 84.6% U.S. rate
95
Durable LVADs implanted (highest annual number to date), including 59 HeartMate 3™ placements
Survival* After LVAD Implant, 1/1/17-9/30/18
Months After Implant
Intermacs Benchmark
(N = 3,859)
Cleveland Clinic
(N = 111)
1
97.6%
(95.1%-98.8%)
94.3%
(93.9%-94.7%)
3
92.5%
(88.9%-94.9%)
90.0%
(89.5%-90.5%)
6
89.5%
(85.3%-92.5%)
87.1%
(86.5%-87.6%)
12
87.4%
(82.7%-90.9%)
82.0%
(81.3%-82.7%)
*Values in parentheses show 70% confidence intervals.
Source: Society of Thoracic Surgeons (STS) Intermacs Database
92
Veno-arterial ECMO cases — double the number from prior year
126
Temporary support devices placed (Impella®and CentriMag™)
LVAD= left ventricular assist device; SRTR = Scientific Registry of Transplant Recipients; ECMO = extracorporeal membrane oxygenation
Electrophysiology (EP)
27,193
EP lab procedure volume,
2014-2018
5,969
EP lab procedure volume, 2018
905
Lead extraction procedures, 2014-2018, with a total of 1,675 leads extracted
97.8%
Clinical success rate
1.7%
Major complication rate, vs. benchmark of 1.8%
4,650
Atrial fibrillation ablations,
2014-2018
1.4%
Major complication rate, vs. benchmark of 4.5%
614
Ventricular arrhythmia ablations in patients with LVEF < 50%, 2014-2018
2.1%
Major complication rate, vs. benchmark of 13%
329
Placements of the Watchman™ device for LAA occlusion, 2016-2018 (includes both EP and interventional cardiology)
2.8%
Residual annual stroke risk for a subgroup of 104 Watchman patients at very high stroke risk (CHA2DS2-VASc score ≥5), as compared with 12% estimated risk for patients not on anticoag-
ulation and >4% risk for those
on warfarin
LVEF = left ventricular ejection fraction; LAA = left atrial appendage
2
2
®
(SRTR report released 1/7/19)
(SRTR report released 1/7/19)
(based on Kusumoto et al., Heart Rhythm. 2017)
(based on Cappato et al., Circ Arrhythm Electrophysiol. 2010)
(based on Stevenson et al., Circulation. 2008)
(data presented at 2018 Heart Rhythm Scientific Sessions, reflecting cases from May 2015 to
November 2017)
and clevelandclinic.org/e15.